Sutro Biopharma, Inc. (STRO) Misses Q1 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St futures muted as oil gains curb risk appetite after S&P record close
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- Reddit to join S&P 500 index on Aug. 18, shares leap
Sutro Biopharma (STRO) PT Lowered to $10 at Deutsche Bank
May 14, 2024 4:12 PM EDTDeutsche Bank analyst James Shin lowered the price target on Sutro Biopharma (NASDAQ: STRO) to $10.00 (from $12.00) while maintaining a Buy rating.
The analyst comments "We're updating our STRO model for 1Q24 results, maintaining our Buy rating and lowering our price target to... More
Wedbush Reiterates Outperform Rating on Sutro Biopharma (STRO)
May 14, 2024 8:25 AM EDTWedbush analyst David Nierengarten reiterated an Outperform rating and $8.00 price target on Sutro Biopharma (NASDAQ: STRO)
The analyst comments "STRO reported 1Q24 earnings. The company continues to advance lead asset luvelta (FolR-targeted ADC) through multiple clinical studies. Part 1 of the registration-directed REFRaME-01 study in... More
